Balance Sheet Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:30:00 17/07/2026 BST			5-day change	1st Jan Change
4,450.00 ^JPY	+2.58%		+3.83%	-4.51%

07-14	Bioarctic AB Partner Eisai Presents Real-World Leader Study Results for Leqembi in Early Alzheimer?S Disease	CI
07-14	Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026	CI

f425f81f8af99b77cefb838.tmQfjfHw7bKJkMq7q4EtITg4Zta_ySWRPKqYlDc2ZEk.xR0s-MjDwOuww73V29JpbEx0VaGIqGOncPLh4H9ZCQX7DCzFoZWL5s7VuQ

Published financial data: EISAI CO., LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2022	2023	2024	2025	2026
Revenues	756B	744B	742B	789B	825B
Total Revenues	756B	744B	742B	789B	825B
Cost of Goods Sold, Total	175B	178B	155B	169B	191B
Gross Profit	581B	567B	586B	621B	634B
Selling General & Admin Expenses, Total	357B	348B	364B	397B	424B
R&D Expenses	172B	173B	169B	172B	159B
Depreciation & Amortization - (IS)	9.58B	10.15B	10.34B	11.39B	11.51B
Other Operating Expenses	792M	-3.16B	-1.11B	-6.09B	-3.93B
Other Operating Expenses, Total	539B	528B	542B	574B	590B
Operating Income	42.44B	38.44B	44.08B	47.07B	44.14B
Interest Expense, Total	-1.43B	-1.66B	-1.88B	-2.76B	-4.23B
Interest And Investment Income	2.21B	5.09B	10.08B	10.06B	8.74B
Net Interest Expenses	780M	3.44B	8.19B	7.31B	4.51B
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	-2.08B	-2.2B	464M	-2.41B	-
Other Non Operating Income (Expenses)	-62M	-60M	-63M	-63M	-65M
EBT, Excl. Unusual Items	41.07B	39.61B	52.68B	51.91B	48.58B
Impairment of Goodwill	-	-	-	-	-
Gain (Loss) On Sale Of Investments	-10M	5.4B	285M	-559M	2.42B
Gain (Loss) On Sale Of Assets	13.4B	-	8.86B	9.71B	-
EBT, Incl. Unusual Items	54.46B	45.01B	61.82B	61.06B	51B
Income Tax Expense	8.74B	-11.82B	18.04B	13.01B	10.48B
Earnings From Continuing Operations	45.72B	56.84B	43.78B	48.06B	40.52B
Net Income to Company	45.72B	56.84B	43.78B	48.06B	40.52B
Minority Interest	2.24B	-1.4B	-1.38B	-1.63B	-1.96B
Net Income - (IS)	47.95B	55.43B	42.41B	46.43B	38.56B
Net Income to Common Incl Extra Items	47.95B	55.43B	42.41B	46.43B	38.56B
Net Income to Common Excl. Extra Items	47.95B	55.43B	42.41B	46.43B	38.56B
Per Share Items
Net EPS - Basic	167.27	193.31	147.86	163.76	136.78
Basic EPS - Continuing Operations	167.27	193.31	147.86	163.76	136.78
Basic Weighted Average Shares Outstanding	287M	287M	287M	284M	282M
Net EPS - Diluted	167.25	193.31	147.86	163.76	136.78
Diluted EPS - Continuing Operations	167.25	193.31	147.86	163.76	136.78
Diluted Weighted Average Shares Outstanding	287M	287M	287M	284M	282M
Normalized Basic EPS	97.34	81.44	110	108.69	100.76
Normalized Diluted EPS	97.32	81.44	110	108.69	100.76
Dividend Per Share	160	160	160	160	160
Payout Ratio	95.67	82.79	108.27	98.09	117.07
American Depositary Receipts Ratio (ADR)	0.25	0.25	0.25	0.25	0.25
Supplemental Items
EBITDA	80.83B	78.42B	83.48B	86.98B	83.69B
EBITA	42.44B	38.44B	44.08B	47.07B	44.14B
EBIT	42.44B	38.44B	44.08B	47.07B	44.14B
Effective Tax Rate - (Ratio)	16.05	-26.27	29.18	21.3	20.55
Normalized Net Income	27.91B	23.35B	31.55B	30.82B	28.4B
Non-Cash Pension Expense	-89M	-89M	-394M	-288M	-235M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	172B	173B	169B	172B	159B

Fiscal Period: March	2022	2023	2024	2025	2026
Assets
Cash And Equivalents	310B	267B	305B	266B	245B
Total Cash And Short Term Investments	310B	267B	305B	266B	245B
Accounts Receivable, Total	208B	187B	217B	220B	227B
Total Receivables	208B	187B	217B	220B	227B
Inventory	99.01B	140B	175B	216B	258B
Other Current Assets, Total	24.02B	27.18B	26.45B	26.17B	31.66B
Total Current Assets	641B	622B	723B	728B	762B
Net Property Plant And Equipment	170B	167B	165B	158B	161B
Long-term Investments	64.95B	73.88B	83.24B	90.78B	71.07B
Goodwill	192B	209B	236B	233B	259B
Other Intangibles, Total	95.45B	89.23B	85.49B	75.26B	88.12B
Deferred Tax Assets Long-Term	76.62B	103B	101B	101B	108B
Other Long-Term Assets, Total	-	1M	-1M	-	0
Total Assets	1,239B	1,263B	1,394B	1,387B	1,449B
Liabilities
Accounts Payable, Total	108B	86.83B	72.25B	91.57B	75.89B
Short-term Borrowings	-	31.2B	24.63B	52.7B	51.3B
Current Portion of Long-Term Debt	-	10B	-	34.99B	-
Current Income Taxes Payable	6.88B	2.22B	8.72B	4.26B	6.67B
Other Current Liabilities	198B	169B	199B	189B	206B
Total Current Liabilities	313B	299B	304B	372B	340B
Long-Term Debt	94.89B	84.9B	135B	99.83B	135B
Pension & Other Post Retirement Benefits	10.83B	11.09B	6.85B	4.85B	3.25B
Deferred Tax Liability Non Current	483M	664M	704M	732M	1.68B
Other Non Current Liabilities	48.24B	45.18B	48.02B	42.87B	44.03B
Total Liabilities	468B	441B	495B	521B	524B
Common Stock, Total	44.99B	44.99B	44.99B	44.99B	44.99B
Additional Paid In Capital	77.6B	78.81B	78.86B	74.84B	74.31B
Retained Earnings	507B	523B	526B	512B	511B
Treasury Stock	-33.94B	-33.64B	-33.61B	-42.29B	-42.29B
Comprehensive Income and Other	154B	187B	259B	252B	311B
Total Common Equity	749B	800B	876B	841B	899B
Minority Interest	22.71B	22.61B	23.36B	24.55B	26.13B
Total Equity	772B	823B	899B	866B	925B
Total Liabilities And Equity	1,239B	1,263B	1,394B	1,387B	1,449B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	287M	287M	287M	282M	282M
ECS Total Common Shares Outstanding	287M	287M	287M	282M	282M
Book Value / Share	2.61K	2.79K	3.05K	2.98K	3.19K
Tangible Book Value	462B	502B	554B	533B	552B
Tangible Book Value Per Share	1.61K	1.75K	1.93K	1.89K	1.96K
Total Debt	94.89B	126B	159B	188B	186B
Net Debt	-215B	-141B	-145B	-78.04B	-59.34B
Debt Equivalent of Unfunded Proj. Benefit Obligation	-6.58B	-7.78B	-21.98B	-28.2B	-16.28B
Minority Interest, Total (Incl. Fin. Div)	22.71B	22.61B	23.36B	24.55B	26.13B
Inventories - Raw Materials, Total	28.23B	67.1B	86.92B	121B	144B
Inventories - Work In Process, Total	25.45B	25.62B	38.59B	39.04B	46.94B
Inventories - Finished Goods, Total	45.33B	47.7B	49.14B	55.62B	66.31B
Inventories - Others	-	-1M	-	-	1M
Full Time Employees	11.32K	11.08K	11.07K	10.92K	10.54K
Accumulated Allowance for Doubtful Accounts (Supple)	575M	701M	783M	690M	1.69B

Fiscal Period: March	2022	2023	2024	2025	2026
Net Income	54.46B	45.01B	61.82B	61.06B	51B
Depreciation & Amortization - CF	38.4B	39.98B	39.4B	39.91B	39.55B
Depreciation & Amortization, Total	38.4B	39.98B	39.4B	39.91B	39.55B
(Gain) Loss From Sale Of Asset	11.43B	2.02B	2.4B	4.29B	1.4B
Other Operating Activities, Total	-20.83B	-27.27B	-20.38B	-27.77B	-17.27B
Change In Accounts Receivable	-40.14B	37.39B	1.5B	-17.24B	-4.46B
Change In Inventories	-6.34B	-36.88B	-21.72B	-43.99B	-24.28B
Change In Accounts Payable	1.03B	4.57B	-11.07B	13.51B	-17.95B
Change in Other Net Operating Assets	79.58B	-66.59B	4.04B	347M	33.32B
Cash from Operations	118B	-1.77B	55.99B	30.12B	61.32B
Capital Expenditure	-29.03B	-22.58B	-14.32B	-11.93B	-15.36B
Sale of Property, Plant, and Equipment	13.44B	576M	1.96B	14.61B	1.5B
Cash Acquisitions	-1.22B	-	-	-260M	-12.58B
Divestitures	-	5.21B	-	-	-
Sale (Purchase) of Intangible assets	-11.44B	-11.98B	-10.5B	-11.04B	-25.81B
Investment in Marketable and Equity Securities, Total	1M	139M	87M	-	5M
Other Investing Activities, Total	-610M	5.91B	-2.55B	-1.48B	10.45B
Cash from Investing	-28.85B	-22.72B	-25.32B	-10.1B	-41.8B
Short Term Debt Issued, Total	-	31.2B	-	28.3B	-
Long-Term Debt Issued, Total	44.87B	-	49.82B	-	35B
Total Debt Issued	44.87B	31.2B	49.82B	28.3B	35B
Short Term Debt Repaid, Total	-	-	-6.57B	-	-4.41B
Long-Term Debt Repaid, Total	-40B	-29M	-10B	-9M	-35.01B
Total Debt Repaid	-40B	-29M	-16.57B	-9M	-39.42B
Repurchase of Common Stock	-	-	-	-30.11B	-9M
Common Dividends Paid	-45.88B	-45.89B	-45.92B	-45.54B	-45.14B
Common & Preferred Stock Dividends Paid	-45.88B	-45.89B	-45.92B	-45.54B	-45.14B
Other Financing Activities, Total	-7.96B	-9.8B	-10.06B	-10.44B	-11.53B
Cash from Financing	-48.97B	-24.52B	-22.72B	-57.81B	-61.1B
Foreign Exchange Rate Adjustments	21.12B	6.74B	29.38B	-1.33B	21.43B
Miscellaneous Cash Flow Adjustments	-1M	-	1M	-1M	1M
Net Change in Cash	60.89B	-42.28B	37.33B	-39.12B	-20.14B
Supplemental Items
Cash Interest Paid	1.29B	1.48B	1.56B	2.55B	3.99B
Cash Income Tax Paid (Refund)	7.11B	22.61B	9.2B	17.84B	13.53B
Levered Free Cash Flow	59.49B	-51.06B	-406M	5.61B	-26.44B
Unlevered Free Cash Flow	60.38B	-50.02B	771M	7.33B	-23.8B
Change In Net Working Capital	-35.93B	79.47B	41.36B	39.03B	49.77B
Net Debt Issued / Repaid	4.87B	31.17B	33.26B	28.29B	-4.42B

Fiscal Period: March	2022	2023	2024	2025	2026
Profitability
Return on Assets	2.28	1.92	2.07	2.12	1.95
Return on Total Capital	3.15	2.65	2.75	2.79	2.55
Return On Equity %	6.1	7.13	5.09	5.45	4.52
Return on Common Equity	6.61	7.16	5.06	5.41	4.43
Margin Analysis
Gross Profit Margin %	76.88	76.11	79.06	78.62	76.83
SG&A Margin	47.19	46.77	49.08	50.24	51.34
EBITDA Margin %	10.69	10.53	11.25	11.02	10.14
EBITA Margin %	5.61	5.16	5.94	5.96	5.35
EBIT Margin %	5.61	5.16	5.94	5.96	5.35
Income From Continuing Operations Margin %	6.05	7.64	5.9	6.09	4.91
Net Income Margin %	6.34	7.45	5.72	5.88	4.67
Net Avail. For Common Margin %	6.34	7.45	5.72	5.88	4.67
Normalized Net Income Margin	3.69	3.14	4.25	3.9	3.44
Levered Free Cash Flow Margin	7.87	-6.86	-0.05	0.71	-3.2
Unlevered Free Cash Flow Margin	7.98	-6.72	0.1	0.93	-2.88
Asset Turnover
Asset Turnover	0.65	0.59	0.56	0.57	0.58
Fixed Assets Turnover	4.57	4.42	4.47	4.89	5.17
Receivables Turnover (Average Receivables)	4.11	3.77	3.67	3.61	3.69
Inventory Turnover (Average Inventory)	1.9	1.49	0.99	0.86	0.81
Short Term Liquidity
Current Ratio	2.04	2.08	2.37	1.95	2.24
Quick Ratio	1.65	1.52	1.71	1.3	1.39
Operating Cash Flow to Current Liabilities	0.38	-0.01	0.18	0.08	0.18
Days Sales Outstanding (Average Receivables)	88.87	96.89	99.79	101.08	98.84
Days Outstanding Inventory (Average Inventory)	192.2	245.7	371.19	422.24	451.85
Average Days Payable Outstanding	195.93	162.23	153.56	142.33	131.24
Cash Conversion Cycle (Average Days)	85.14	180.37	317.41	380.99	419.45
Long Term Solvency
Total Debt/Equity	12.3	15.33	17.73	21.65	20.11
Total Debt / Total Capital	10.95	13.29	15.06	17.8	16.75
LT Debt/Equity	12.3	10.32	14.99	11.53	14.57
Long-Term Debt / Total Capital	10.95	8.95	12.73	9.48	12.13
Total Liabilities / Total Assets	37.75	34.89	35.5	37.54	36.16
EBIT / Interest Expense	29.7	23.18	23.4	17.09	10.44
EBITDA / Interest Expense	56.57	47.3	44.31	31.57	19.8
(EBITDA - Capex) / Interest Expense	36.25	33.68	36.71	27.24	16.17
Total Debt / EBITDA	1.17	1.61	1.91	2.16	2.22
Net Debt / EBITDA	-2.66	-1.8	-1.74	-0.9	-0.71
Total Debt / (EBITDA - Capex)	1.83	2.26	2.3	2.5	2.72
Net Debt / (EBITDA - Capex)	-4.15	-2.53	-2.1	-1.04	-0.87
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	17.07	-1.56	-0.36	6.42	4.56
Gross Profit, 1 Yr. Growth %	19.97	-2.55	3.5	5.83	2.19
EBITDA, 1 Yr. Growth %	-9.7	-2.99	6.46	4.19	-3.78
EBITA, 1 Yr. Growth %	-20.26	-9.43	14.7	6.77	-6.23
EBIT, 1 Yr. Growth %	-20.26	-9.43	14.7	6.77	-6.23
Earnings From Cont. Operations, 1 Yr. Growth %	7.61	24.32	-22.97	9.76	-15.69
Net Income, 1 Yr. Growth %	13.85	15.59	-23.5	9.49	-16.96
Normalized Net Income, 1 Yr. Growth %	-13.99	-16.32	35.09	-2.31	-7.84
Diluted EPS Before Extra, 1 Yr. Growth %	13.85	15.58	-23.51	10.76	-16.47
Accounts Receivable, 1 Yr. Growth %	29.72	-9.95	16	1.3	3.17
Inventory, 1 Yr. Growth %	16.32	41.82	24.38	23.62	19.29
Net Property, Plant and Equip., 1 Yr. Growth %	5.59	-1.94	-1.04	-4.13	1.87
Total Assets, 1 Yr. Growth %	13.7	1.94	10.33	-0.52	4.51
Tangible Book Value, 1 Yr. Growth %	9.19	8.73	10.33	-3.8	3.56
Common Equity, 1 Yr. Growth %	6.49	6.83	9.46	-3.91	6.84
Cash From Operations, 1 Yr. Growth %	59.22	-101.51	-3.26K	-46.21	103.62
Capital Expenditures, 1 Yr. Growth %	51.61	-22.23	-36.57	-16.67	28.71
Levered Free Cash Flow, 1 Yr. Growth %	117.84	-185.83	-99.2	-1.48K	-571.72
Unlevered Free Cash Flow, 1 Yr. Growth %	115.39	-182.84	-101.54	850.22	-424.81
Dividend Per Share, 1 Yr. Growth %	0	0	0	0	0
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	4.27	7.35	-0.96	2.98	5.49
Gross Profit, 2 Yr. CAGR %	5.75	8.12	0.43	4.66	3.99
EBITDA, 2 Yr. CAGR %	-28.11	-6.41	1.63	5.32	0.12
EBITA, 2 Yr. CAGR %	-41.19	-15.02	1.93	10.67	0.06
EBIT, 2 Yr. CAGR %	-41.19	-15.02	1.93	10.67	0.06
Earnings From Cont. Operations, 2 Yr. CAGR %	-38.9	15.67	-2.14	-8.05	-3.8
Net Income, 2 Yr. CAGR %	-37.25	14.72	-5.96	-8.48	-4.64
Normalized Net Income, 2 Yr. CAGR %	-39.6	-15.16	6.32	14.88	-5.12
Diluted EPS Before Extra, 2 Yr. CAGR %	-37.25	14.71	-5.98	-7.96	-3.82
Accounts Receivable, 2 Yr. CAGR %	7.48	8.08	2.2	8.4	2.23
Inventory, 2 Yr. CAGR %	22.73	28.44	32.82	24	21.43
Net Property, Plant and Equip., 2 Yr. CAGR %	8.39	1.76	-1.49	-2.6	-1.18
Total Assets, 2 Yr. CAGR %	8.02	7.66	6.05	4.76	1.96
Tangible Book Value, 2 Yr. CAGR %	6.98	8.96	9.53	3.02	-0.19
Common Equity, 2 Yr. CAGR %	5.08	6.66	8.14	2.56	1.33
Cash From Operations, 2 Yr. CAGR %	6.96	-84.51	-30.99	312.26	4.65
Capital Expenditures, 2 Yr. CAGR %	37.91	8.58	-29.76	-27.3	3.56
Levered Free Cash Flow, 2 Yr. CAGR %	11.14	36.74	-91.74	-66.87	706.65
Unlevered Free Cash Flow, 2 Yr. CAGR %	11.16	33.58	-88.7	-61.73	455.56
Dividend Per Share, 2 Yr. CAGR %	0	0	0	0	0
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	5.56	2.28	4.72	1.44	3.5
Gross Profit, 3 Yr. CAGR %	8.25	2.9	6.56	2.2	3.83
EBITDA, 3 Yr. CAGR %	-10.52	-20.55	-2.3	2.47	2.19
EBITA, 3 Yr. CAGR %	-20.97	-32.08	-6.08	3.52	4.72
EBIT, 3 Yr. CAGR %	-20.97	-32.08	-6.08	3.52	4.72
Earnings From Cont. Operations, 3 Yr. CAGR %	-11.74	-22.58	1.01	1.68	-10.67
Net Income, 3 Yr. CAGR %	-8.88	-23.07	0.23	-1.07	-11.4
Normalized Net Income, 3 Yr. CAGR %	-18.99	-32.67	-0.93	3.36	6.74
Diluted EPS Before Extra, 3 Yr. CAGR %	-8.89	-23.08	0.22	-0.7	-10.89
Accounts Receivable, 3 Yr. CAGR %	9.91	1.32	10.66	1.9	6.63
Inventory, 3 Yr. CAGR %	13.4	28.79	27.07	29.68	22.41
Net Property, Plant and Equip., 3 Yr. CAGR %	17.34	4.83	0.81	-2.38	-1.13
Total Assets, 3 Yr. CAGR %	4.97	5.95	8.54	3.81	4.68
Tangible Book Value, 3 Yr. CAGR %	8.86	7.56	9.41	4.89	3.2
Common Equity, 3 Yr. CAGR %	6.03	5.66	7.58	3.96	3.97
Cash From Operations, 3 Yr. CAGR %	4.27	-74.17	-8.82	-36.49	225.88
Capital Expenditures, 3 Yr. CAGR %	16.91	13.94	-9.23	-25.65	-12.05
Levered Free Cash Flow, 3 Yr. CAGR %	3.7	1.97	-75.4	-54.5	-19.7
Unlevered Free Cash Flow, 3 Yr. CAGR %	3.69	0.78	-69.81	-50.49	-21.93
Dividend Per Share, 3 Yr. CAGR %	2.17	0	0	0	0
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	7	4.41	2.9	2.56	5.02
Gross Profit, 5 Yr. CAGR %	11.12	7.28	5.05	3.6	5.53
EBITDA, 5 Yr. CAGR %	0.75	-5.15	-5.85	-11.07	-1.34
EBITA, 5 Yr. CAGR %	-3.75	-12.74	-12.51	-17.44	-3.67
EBIT, 5 Yr. CAGR %	-3.75	-12.74	-12.51	-17.44	-3.67
Earnings From Cont. Operations, 5 Yr. CAGR %	1.59	0.87	-8.01	-17.06	-0.94
Net Income, 5 Yr. CAGR %	4.03	1.35	-7.72	-17.54	-1.75
Normalized Net Income, 5 Yr. CAGR %	0.15	-12.18	-9.68	-16.63	-2.63
Diluted EPS Before Extra, 5 Yr. CAGR %	4.01	1.33	-7.73	-17.36	-1.42
Accounts Receivable, 5 Yr. CAGR %	6.12	4.33	6.76	4.09	7.2
Inventory, 5 Yr. CAGR %	3.62	11.65	20.8	26.85	24.79
Net Property, Plant and Equip., 5 Yr. CAGR %	10.41	10.09	9.41	1.79	0.01
Total Assets, 5 Yr. CAGR %	3.75	3.79	5.4	5.48	5.86
Tangible Book Value, 5 Yr. CAGR %	9.14	9.34	9.13	5.72	5.47
Common Equity, 5 Yr. CAGR %	5.08	6.15	6.87	4.41	5.04
Cash From Operations, 5 Yr. CAGR %	9.16	-58.82	-11.6	-21.77	-3.65
Capital Expenditures, 5 Yr. CAGR %	29.98	16.55	-4.65	-4.8	-4.31
Levered Free Cash Flow, 5 Yr. CAGR %	13.04	-17.14	-62.3	-34.96	-0.64
Unlevered Free Cash Flow, 5 Yr. CAGR %	12.21	-17.7	-57.28	-31.58	-3.22
Dividend Per Share, 5 Yr. CAGR %	1.3	1.3	1.3	0	0